Coagulation Factor Deficiency Market to Witness Significant Innovation and Growth by 2034 | Predicts DelveInsight

The Coagulation Factor Deficiency market is evolving rapidly, fueled by advances in gene therapy, long-acting clotting factors, and better prophylaxis. DelveInsight's report covers epidemiology and treatments for Hemophilia A, B, and rare factor deficiencies (FVII, FXI, FXIII). AAV-based gene therapies are driving new treatment goals and improving outcomes, especially for underserved patients.
DelveInsight's "Coagulation Factor Deficiency Market Report [https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" delivers detailed analysis of market dynamics, historical and forecasted epidemiology, and emerging therapies across the 7MM (US, EU5, and Japan), highlighting key players and trends driving this rare disease segment.

Some of the Key Facts of the Coagulation Factor Deficiency Market Report:

- In 2023, the coagulation factor deficiency market in the 7MM was valued at approximately USD 13.5 billion.

- The US led the market, contributing around USD 7.2 billion.

- There were about 105K prevalent cases across the 7MM, with the US accounting for nearly 34K.

- Hemophilia A was the most common subtype among all coagulation factor deficiencies.

- Marketed drugs for coagulation factor deficiency include ESPEROCT (Novo Nordisk), JIVI (Bayer), and WILATE (Octapharma).

- In March 2025, the FDA approved QFITLIA (fitusiran) for routine prophylaxis to reduce bleeding episodes in patients (12+) with hemophilia A or B, with or without factor VIII or IX inhibitors.

- In December 2024, Novo announced that the FDA approved concizumab, its tissue factor pathway inhibitor (TFPI) antagonist, as a once-daily treatment to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B with inhibitors.

- In October 2024, Novo Nordisk received support from European regulators for the approval of its anti-TFPI antibody, Alhemo (concizumab), as a preventive treatment for hemophilia. The company stated that, if approved, this therapy would provide the first subcutaneous prophylactic treatment to be administered once daily for individuals with hemophilia A or B who have inhibitors.

- In March 2024, ReciBioPharm signed a collaboration agreement with GeneVentiv Therapeutics, a preclinical gene therapy company, to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, and reportedly the first to treat hemophilia patients with inhibitors.

- Emerging coagulation factor deficiency drugs include Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.

- Leading companies in the coagulation factor deficiency market include Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.

- The rising incidence of coagulation factor deficiencies, along with ongoing advancements in treatment options, is driving the demand for more effective therapies for these conditions.

To know in detail about the coagulation factor deficiency market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Coagulation Factor Deficiency Market Forecast [https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Coagulation Factor Deficiency Overview

Coagulation factor deficiencies, also referred to as bleeding or clotting disorders, are a group of inherited or acquired conditions caused by the absence or dysfunction of specific proteins that are essential for blood clotting. These proteins, known as coagulation factors, are vital for halting bleeding by forming clots to close off damaged blood vessels.

There are 13 coagulation factors, each numbered from I to XIII, that work together in a complex process to maintain hemostasis. Deficiencies in any of these factors can lead to abnormal bleeding, with severity varying based on the specific factor affected and the extent of the deficiency.

Get a free sample of the coagulation factor deficiency market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market [https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Coagulation Factor Deficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Coagulation Factor Deficiency Epidemiology Segmentation:

The coagulation factor deficiency epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

- Total diagnosed prevalent cases

- Factor-specific prevalent cases

Download the report to understand which factors are driving coagulation factor deficiency epidemiology trends @ Coagulation Factor Deficiency Epidemiology Forecast [https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Coagulation Factor Deficiency Drugs Uptake, and Pipeline Development Activities

The coagulation factor deficiency drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the coagulation factor deficiency market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the coagulation factor deficiency pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Coagulation Factor Deficiency Market Strengths

- New gene therapies for coagulation factor deficiencies, like Hemophilia A and B, offer potential long-term or curative solutions.

- Better awareness and diagnostic tools are enabling earlier detection and more effective management.

Coagulation Factor Deficiency Market Weaknesses

-Many therapies, particularly gene therapies, remain expensive, limiting accessibility.

- Advanced therapies are not widely accessible in lower-income regions due to cost and healthcare limitations.

Scope of the Coagulation Factor Deficiency Market Report

- Study Period: 2020-2034

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Coagulation Factor Deficiency Therapies: Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.

- Key Coagulation Factor Deficiency Companies: Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.

- Coagulation Factor Deficiency Therapeutic Assessment: Coagulation factor deficiency, currently marketed, and coagulation factor deficiency emerging therapies

- Coagulation Factor Deficiency Market Dynamics: Coagulation factor deficiency market drivers and Coagulation Factor Deficiency market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Coagulation Factor Deficiency Unmet Needs, KOL's views, Analyst's views, Coagulation Factor Deficiency Market Access and Reimbursement

To learn more about the key players and advancements in the coagulation factor deficiency treatment landscape, visit the Coagulation Factor Deficiency Market Analysis Report [https://www.delveinsight.com/report-store/coagulation-factor-deficiency-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Coagulation Factor Deficiency Market Report Introduction

2. Executive Summary for Coagulation Factor Deficiency

3. SWOT analysis of Coagulation Factor Deficiency

4. Coagulation Factor Deficiency Patient Share (%) Overview at a Glance

5. Coagulation Factor Deficiency Market Overview at a Glance

6. Coagulation Factor Deficiency Disease Background and Overview

7. Coagulation Factor Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Coagulation Factor Deficiency

9. Coagulation Factor Deficiency Current Treatment and Medical Practices

10. Coagulation Factor Deficiency Unmet Needs

11. Coagulation Factor Deficiency Emerging Therapies

12. Coagulation Factor Deficiency Market Outlook

13. Country-Wise Coagulation Factor Deficiency Market Analysis (2020-2034)

14. Coagulation Factor Deficiency Market Access and Reimbursement of Therapies

15. Coagulation Factor Deficiency Market Drivers

16. Coagulation Factor Deficiency Market Barriers

17. Coagulation Factor Deficiency Appendix

18. Coagulation Factor Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=coagulation-factor-deficiency-market-to-witness-significant-innovation-and-growth-by-2034-predicts-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.